All Industries

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp.

Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? Kelowna, British Columbia – May 17, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that d osing has begun in the 12-week animal study WEIGHT-A24-1 (the “ Study ”) to model diabetes treatment and weight loss effects of DehydraTECH™-processed glucagon-like peptide 1 (“ GLP-1 ”) drugs and DehydraTECH-processed cannabidiol (“ CBD ”), alone and in combination in diabetic preconditioned rats. What’s New There are several important new areas of investigation to be explored within this broad study. Are DehydraTECH-processed oral GLP-1 drugs more effective than non DehydraTECH-processed oral GLP-1 drugs in: Reaching brain tissue? Improving weight loss? Improving control of blood sugar? Combining with CBD for improved results? One arm of this 12-arm study will, for the first time, evaluate DehydraTECH-processed pure semaglutide and compare it to re-formulated Rybelsus® processed with DehydraTECH, containing Novo Nordisk’s SNAC® ( salcaprozate sodium ) technology. Another arm will, also for the first time, evaluate DehydraTECH-processed liraglutide. Liraglutide is a GLP-1 drug marketed in injectable form by Novo Nordisk under the brand names Victoza® and Saxenda®. Animals in each of the first 8 study arms are being dosed with the following: 1 pure liraglutide DehydraTECH composition; 1 pure semaglutide DehydraTECH composition; 2 reformulated Ryblesus® DehydraTECH compositions; and 4 different DehydraTECH-CBD compositions Study arms 9 through 12 will begin when the first 8 study arms have completed. Based on the results of the initial 8 study arms, study arms 9 and 10 will each utilize the best-performing DehydraTECH-CBD composition with the DehydraTECH-liraglutide composition, and separately, the best performing DehydraTECH-semaglutide composition. Study arms 11 and 12 are placebo and positive control arms. About the Study Each arm of the Study will be dosed for a 12-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. The Study will also include a comprehensive battery of liver and kidney function testing and blood chemistry analyses. LC-MS/MS and other techniques will be used to analyse samples. Lexaria will be collecting and reporting interim results prior to the end of the Study. Why Does Brain Absorption Matter? In previous animal research with two other molecules, including CBD, Lexaria demonstrated through brain tissue examination that DehydraTECH processing enabled higher levels of drug delivery into brain tissue. Study WEIGHT-A24-1 is designed to further validate whether DehydraTECH processing can similarly deliver higher quantities of GLP-1 drugs into brain tissue. Recent research has indicated “ that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R–expressing neurons in the arcuate nucleus to produce weight loss.” Lexaria believes that, if it can evidence that DehydraTECH processing of GLP-1 drugs can enable greater penetration into brain tissue, then this may help to explain how the GLP-1 drug(s) powered by DehydraTECH may be more effective at enhancing beneficial outcomes such as weight loss and blood sugar control. In turn, this could also potentially allow for lower dosing and a concomitant reduction in adverse side effects. About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com. CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. INVESTOR CONTACT: George Jurcic - Head of Investor Relations ir@lexariabioscience.com Phone: 250-765-6424, ext 202

May 17, 2024 09:10 AM Eastern Daylight Time

British Ambassador, Scottish Government, and the Keepers of the Quaich, Host Rare Scotch Tasting to Raise Scholarship Funds

Keepers of the Quaich

The British Ambassador Dame Karen Pierce, DCMG, the Scottish Government, and the Keepers of the Quaich USA (KOTQUSA.org), the US arm of the international Scotch heritage society, hosted a gala at the Ambassador’s official residence to celebrate the King of Spirits and raise scholarship funds. This exclusive gathering to sample rare whiskies and new expressions brought together a distinguished group of guests, including members of Congress; senior Administration officials; media; top industry executives; major trade association heads; other ambassadors; and members of Keepers of the Quaich USA society. The evening benefited the Entrepreneurial Scotland Foundation (EntrepreneurialScotland.com), a charity dedicated to creating scholarship opportunities in the U.S. for Scottish students, many of whom are first-generation college students, and the foundation's support plays a vital role in their academic success. The Ambassador welcomed the 2024 Gathering saying, “Thank you for joining us in celebrating Scotch Whisky, while raising funds for ESF scholarships. These rarities and new expressions demonstrate the range and vibrancy of the category and its long heritage. From the Highlands to Speyside, from Orkney to Islay, the diversity of Scotland’s whiskies is treasured around the globe.” Chris Thomson, Head of the Scottish Government in the USA, added, “We are delighted to be able to support Keepers of the Quaich USA and the Entrepreneurial Scotland Foundation, bringing top students at Scottish universities to the US for internships. Scotland is rightly proud of our whisky, and also of our incredible higher education sector – both contribute both to stronger communities and economies at home, and to our transatlantic relationship with the US. To be able to support both tonight, and sample these incredible whiskies, is a great pleasure.” KOTQUSA Co-chair and Diageo NA CMO Ed Pilkington pointed out, “While Scotch whisky is exported to well over 100 countries around the globe, the United States is by far its most valuable market.” KOTQUSA Co-chair Frank Coleman added, “American consumers continue to savor super premium blends and single malts, with over nine million cases sold last year, worth over $2.5 billion to distillers, and much more to distributors and retailers across the country.” The event featured eight individual company sampling tables as well as a full bar where cocktails were served with premium mixers provided by Fever Tree. In the fountain courtyard there was a cigar lounge sponsored by Cigar Aficionado magazine. The guests also enjoyed pairing the whiskies with a lavish buffet of fresh Scottish seafood supplied by Seafood Scotland —artfully prepared by embassy Chef Craig Harnden, as well as cheese provided by Lactalis and oatcakes provided by Nairn’s. Keeping Scottish tradition alive, the evening’s toast featured the Scottish Quaich, also known as the ‘Cup of Friendship,’ the two-handled drinking vessel that dates back to the 16th century, from which the Society takes its name. Founded in 1988 and headquartered at Blair Castle in the Scottish Highlands, the Keepers of the Quaich honors individuals who have made significant contributions to the world of Scotch whisky. With around 3000 Keepers from more than 100 countries, the society fosters camaraderie and appreciation for this iconic spirit. The US Chapter has approximately 300 members, many from C-Suites of all three tiers of the industry. Participating companies and brands served included: DIAGEO: Lagavulin Offerman Rum Cask Edition; Lagavulin 16; Oban 14; Johnnie Walker King George V DEWAR’S/BACARDI: Dewar’s Double-Double 21yr Mizunara Cask Finish; Dewar’s Double-Double 37yr Blended Malt; Dewar’s 18yr BROWN FORMAN: The Glendronach 12; Glenglassaugh Sandend; The Glendronach Hand-Filled; Glenglassaugh 40yr; The Glendronach Grandeur SUNTORY GLOBAL SPIRITS: Laphroaig Single Cask-Jack Rose Dining Saloon; Bowmore 15; Ardray Blend; Laphroaig Sherry Oaked EDRINGTON: The Macallan Rare Cask; Highland Park 12; The Macallan 12yr Sherry Oak PERNOD RICARD: The Glenlivet Fusion Cask; The Glenlivet 18yr; Royal Salute 21yr; Aberlour A’Bunadh RÉMY COINTREAU: Bruichladdich Classic Laddie; Bruichladdich Islay Barley 2014; Bruichladdich Eighteen; Port Charlotte 10 WILLIAM GRANT & SONS: Glenfiddich 12 year Old Sherry Cask Finish; Glenfiddich 14yr Bourbon Barrel Reserve; Glenfiddich 21yr Gran Reserva; Balvenie 16yr French Oak Contact Details Danielle Eddy +1 914-414-0041 deddy213@gmail.com

May 17, 2024 08:46 AM Eastern Daylight Time

Image

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Benzinga

By James Blacker, Benzinga Some 42% of adults in the United States are affected by obesity, according to the U.S. CDC. At a global level, a new study released by the journal Lancet reveals that around 1 billion people are now living with obesity, with the number of obese adults having doubled since 1990 and quadrupled among children and adolescents. The demand for solutions to escalating obesity rates is only growing. Goldman Sachs Research notes that the global market for anti-obesity drugs reached $6 billion on an annualized basis in 2023 and this global market is projected to experience a more than 16-fold increase to $100 billion by 2030. The global growth of anti-obesity drugs is expected to be led by drugs such as Ozempic ® and Wegovy ®, both manufactured by Novo Nordisk (NYSE: NVO), as well as Mounjaro ®, made by Eli Lilly And Co (NYSE: LLY). However, there are concerns that GLP-1 drugs like Ozempic ® and Wegovy ® might lead to a loss of muscle mass along with fat mass. This potential side effect highlights a need for new or coinciding treatments that can address obesity while limiting such side effects. Revolutionizing Obesity Treatment Medical aesthetics and biopharmaceutical drug development company Elevai Labs Inc. (NASDAQ: ELAB) is working to address this problem. The firm announced on May 2 that it acquired exclusive rights to two new assets that have the potential to limit muscle loss prevention to develop in combination with GLP-1 obesity treatments – namely “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”, a preclinical engineered probiotic expressing dual myostatin & activin-A. “We believe the adoption and use of other GLP-1 drugs […] increases the desire for related aesthetic procedures linked to the side effects from these drugs, including significant unwanted muscle loss. We see the licensing of these two assets as an opportunity to provide an unmet need in the anti-obesity drug market and expand our brand into a large and growing multi-billion-dollar market,” said Elevai Labs CEO Jordan R. Plews. Elevai plans to test how effective and safe EL-22 is in combination with weight-loss medications currently available on the market. It expects to submit an Investigational New Drug application to the FDA in 2025 and hopes to initiate clinical trials in the U.S. soon thereafter. New Subsidiaries In line with its growth in the biotech industry, Elevai Labs announced on May 1 it launched two new wholly-owned subsidiaries — Elevai Biosciences and Elevai Skincare. Elevai Biosciences will focus on acquiring and developing cutting-edge aesthetic medicines, with EL-22 as its lead asset. Elevai Skincare is a new entity that will continue to advance the company’s skincare solutions. The company hopes that the reorganization of its skincare operations will boost focus, agility, and market penetration in order to capitalize on emerging opportunities in the medical aesthetics skincare market. Commenting on the announcement, Co-founder and CEO Jordan R. Plews stated, “The launch of Elevai Biosciences, Inc. and Elevai Skincare, Inc. as wholly-owned operating subsidiaries signifies a significant milestone in our journey towards reshaping the future of medical aesthetics and biotech. With Elevai Biosciences, we believe we are poised to lead the development of next-generation aesthetic medicines, while Elevai Skincare will continue to develop and deliver exceptional cosmetic solutions to our customers worldwide.” Featured photo by Prostock-studio on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Elevai's expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for EL-22; and the potential of EL-22 to treat obesity without an associated loss of muscle, both as a monotherapy and in combination with GLP-1 receptor agonists. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Elevai's limited operating history and historical losses; Elevai's ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai's dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai's ability to obtain, maintain and protect its intellectual property; and Elevai's dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in Elevai's filings with the Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 17, 2024 08:45 AM Eastern Daylight Time

Image

Dissatisfied By Candidates This Election? Check Out The Latest Meme Coin Revolution Mixing Politics With Crypto Profits And Some Laughs

Benzinga

By Austin DeNoce, Benzinga As the 2024 U.S. presidential election draws near, an unprecedented level of dissatisfaction seems evident among voters regarding the two leading candidates. Current polling data from 538 reveals that both former President Donald Trump and current President Joe Biden are struggling with unfavorable ratings – 53% for Trump and 55% for Biden. This general discontent reflects a unique scenario in American politics where both major-party candidates are simultaneously unpopular – which is a rare occurrence historically. The dynamics of this election thus seem to be less about choosing the more popular candidate and more about dealing with the deep-seated disapproval each candidate garners. But voters who are also crypto enthusiasts can now find solace in a new guilty pleasure: political meme coins. The Rise Of Political Meme Coins In this atmosphere of widespread voter dissatisfaction, political meme coins have emerged as a novel form of relief, adding a touch of humor and levity to the electoral process. There are already meme coins about Tucker Carlson ($TOOKER) and Alex Jones ($JOWNES), among others. Noteworthy among these is the $TREMP coin inspired by former President Donald Trump. These digital tokens, while initially created for amusement, have started to carve out a niche within the crypto community. The introduction of meme coins like $TREMP into the political discourse is providing a light-hearted alternative to the typically grave discussions surrounding presidential campaigns and giving voters a unique opportunity to speculate on politics or, at the very least, have a laugh at their growing popularity and humorous commentary on current events. A lot of these coins, like $TREMP, emulate real-world events and engage other politically inspired meme coins in the community. However, unlike real-world election conversation, the back and forth between crypto-candidates and Polifi tokens is light-hearted and also meant to entertain. Spotlight On $TREMP Coin The $TREMP coin was launched on February 28 and saw a rapid rise in interest and market cap, reaching $100 million within its first month. To put that in perspective, CoinGecko data puts the total market cap for “PolitiFi” coins – as these new coins are called – at about $690 million as of May 13 and growing, up over 20% in the prior 24 hours. After the original creator of the $TREMP coin stepped back, the community took over, propelling $TREMP into a prominent position among political meme coins. The involvement of figures such as Anatoly Yakovenko from Solana Labs has further legitimized its presence in the crypto world. Recently, the $TREMP team announced the recruitment of Dustin Stockton, a known conservative strategist who previously worked for the Newt Gingrich Presidential campaign in 2012 and under Steve Bannon at Breitbart in the lead-up to 2016, emphasizing their commitment to mimic real-world political campaigns in a satirical yet engaging manner. This has not only increased its visibility but also highlighted the potential of meme coins to influence political narratives in real time. It may also be a catalyst for broader political and regulatory discussions about the crypto industry and its future role in finance. Trump’s Crypto Endorsements And $TREMP Donald Trump’s recent pro-crypto comments at a gathering in Mar-a-Lago mark a significant pivot in his stance toward the cryptocurrency industry, which is in contrast to the Biden administration's more stringent regulatory approach. Trump’s endorsement has also stirred considerable interest in political meme coins, particularly $TREMP, reflecting the irony of how these ‘joke’ tokens are increasingly becoming a topic of legitimate discussion in political campaigning. As these tokens gain traction, they offer a unique and humorous lens through which the public can engage with the often polarizing figures of real-world politics. This is the first election where such a thing is possible, blurring the lines between satire and serious political commentary. Political meme coins like $TREMP demonstrate the changing landscape of voter engagement and discourse, providing a unique, albeit unconventional, way to engage in and speculate on the electoral process. Featured photo by Element5 Digital on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 17, 2024 08:35 AM Eastern Daylight Time

Image

Pioneering Education With AI-Driven EdTech Firm Amesite (NASDAQ: AMST): Insights From CEO Dr. Ann Marie Sastry

Benzinga

By James Blacker Amesite Inc (NASDAQ: AMST) CEO Dr. Ann Marie Sastry spoke with Benzinga recently about the company’s mission and the transformative role of Artificial Intelligence (AI) in education. Below, we take a look at the key insights gathered from the interview, including Amesite’s unique approach and vision for the future. What Is Amesite? Amesite is an AI software company dedicated to building platforms and apps that facilitate learning. Their focus ranges from colleges and universities to individual consumers, with an emphasis on accessibility and effectiveness in education. What Sets Amesite Apart From Its Competitors? Other names in the space include Coursera Inc (NYSE: COUR), 2U Inc (NASDAQ: TWOU) and Udemy Inc (NASDAQ: UDMY). According to Dr. Sastry, Amesite gets its competitive edge from the use of AI coupled with a student-centric approach. The company aims to provide not just content but also the tools necessary for success. This is especially true for professional learning, Dr. Sastry noted, which is a lifelong endeavor and has a big impact on financial security and career growth. Amesite’s approach appears to be paying off, as in February the company reported an overall retention rate of 98% for paid learning experiences on its platform, far exceeding the industry average of 68-73%. Why Is Amesite Focused On Education? Continuous upskilling is essential in the world of work. Most of what people do on a daily basis is learned after formal education. The CEO highlighted the pitfalls of traditional learning management systems, which are mainly content repositories and lack a well-designed user experience. Course aggregators, meanwhile, offer courses on everything, making it difficult for consumers to pick out exactly what they need. Amesite, therefore, sees its partnership model with colleges and universities as an ideal way to curate relevant content and tools, addressing the diverse learning needs of individuals and ensuring localized, impactful education solutions. What Does Amesite Foresee Will Be The Next Evolution Of AI In This Space? Amesite invested early in AI and was discussing the technology even back when the company was founded in 2018, shared Dr. Sastry. In April, the company announced the beta release of its new NurseMagic TM app, which uses AI to provide helpful and easy-to-use tools for over 5.2 million nurses. Dr. Sastry sees this strategic shift towards mobile apps as a way to provide people with faster access to AI-powered learning tools. “Surf the AI wave. Make sure you have access to those tools so you can be competitive. That’s something we’re extremely excited about,” she said. Key Targets And Goals For The Company Amesite recently moved to a no-fee model for its higher ed platform, where customers pay monthly per user instead of paying set-up fees. Since then, the company has announced several five-year deals with colleges and universities. It most recently partnered with Volunteer State Community College and Joliet Junior College in March. These partnerships enable tailored learning experiences, addressing regional needs and industry demands. Dr. Sastry highlighted implicit bias training and active shooter preparedness as programs that Amesite now makes available nationwide, as this is a work requirement for many. In March, the company also announced a partnership with Partners for Advancing Clinical Education (PACE) to deliver accredited healthcare education. What's Behind Your Recent Momentum With Five Contract Wins With Various Colleges? Dr. Sastry attributes Amesite’s success to a tailored approach that caters to each institution's unique needs, especially when it comes to aligning with regional requirements and legislative shifts. “By working directly with colleges and universities and generating sustainable revenue, we can actually give the people what they want,” she said. “With our 98% retention, we are a very strong argument for colleges and universities to use the Amesite system, generate impact, and meet the needs that are required from legislators and assemblies.” Watch the full interview here. Featured photo by Compare Fibre on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 17, 2024 08:30 AM Eastern Daylight Time

Video Image

How WiSA Technologies’ (NASDAQ: WISA) Latest Product, WiSA E, Is Revolutionizing The Audio Industry

Benzinga

By Faith Ashmore, Benzinga WiSA Technologies (NASDAQ: WISA) has emerged as a leader in the audio and video entertainment sector through its pioneering wireless technology. With its latest innovation launched in 2023, WiSA E, the company looks poised to revolutionize the industry and solidify its position as the premier solution for high-quality wireless audio for home entertainment (across multiple channels). This innovative spatial audio technology offers up to eight independent channels of HD audio, providing an immersive listening experience. WiSA E transmits and receives uncompressed 24-bit 48 kHz sound over a 5 GHz Wi-Fi network. As a result, users can enjoy high-quality audio without any lag or latency issues. One of the key features of WiSA E is its interoperability with other certified WiSA E-enabled devices. The WiSA Association has established an interoperability standard that certifies products as compatible with each other, thus creating an industry benchmark for superior audio quality. This means that WiSA E-enabled products can work flawlessly with any other certified WiSA E-enabled device, providing a hassle-free setup. “This is a game changer in the industry,” shared Brett Moyer, CEO of WiSA Technologies. “WiSA E will be used by a major CE manufacturer to embed high-quality immersive audio functionality in their devices – functionality that can be activated by the consumer in their home. This is significant because this new model seeds the market with WiSA E and gives the consumer the ability to upgrade their home entertainment system at any time they choose. With this model, WiSA has a built-in aftermarket revenue stream for the major consumer electronics TV, projector, and set-top manufacturers with each activation of its software. This was a strategic move for WiSA Technologies to convert its award-winning hardware into a software model.” WiSA Technologies Has Always Focused On Elevating Industry Standards From the beginning, the company focused on assembling talented teams across various departments, including research and development, sales, marketing and management. This strong foundation allowed WiSA to consistently prioritize innovation and deliver superior entertainment experiences. The formation of the WiSA Association was a pivotal moment in the company's trajectory. With over 70 members, the association has helped foster relationships with leading consumer electronics manufacturers. To ensure the success of WiSA E, WiSA Technologies has also introduced the Propel program, which encompasses several strategic initiatives. These initiatives include efforts to standardize industry solutions, achieve consistent revenue performance, reduce infrastructure costs and maximize long-term shareholder value. By forging partnerships with TV/audio speaker and chip manufacturers, WiSA Technologies aims to create new revenue streams through enhanced WiSA E technology. The company has developed stringent specifications compliance and fostered close working relationships with consumer electronics manufacturers and chip makers, enabling WiSA to produce high-volume, lower-cost solutions that will have a direct impact on the company's bottom line. By expanding interbrand operability among premier audio manufacturers and delivering premium technology solutions to mass-market audio systems, WiSA is solidifying its position as an industry innovator. Featured photo by Mollie Sivaram on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 17, 2024 08:25 AM Eastern Daylight Time

Image

Token Terminal and Messari Release Research Reports on TRON Network For Q1 of 2024

TRON DAO

Geneva, Switzerland, May 17, 2024 – Recent detailed analyses by Token Terminal and Messari have provided an in-depth review of the TRON network’s activity during the first quarter of 2024, emphasizing its competitive positioning and expansive growth within the blockchain sector. Token Terminal Analysis Token Terminal’s comprehensive report offers crucial insights into key data points and metrics of the TRON networks, setting it apart from comparable blockchain networks: Daily Transaction Fees: TRON leads with $4.4 million in daily transaction fees, significantly higher than its peers, highlighting the network’s robust activity and utility. Daily Active Users: Averaging 1.6 million daily active users across Q1, TRON is a leading blockchain for user activity, demonstrating a vibrant and engaged user base that supports continuous network growth. Transaction Volume and Efficiency: TRON’s high transaction volume and operational efficiency underscore its strong infrastructure, which is optimized to handle extensive activity without compromising speed or cost. Messari’s Comprehensive Insights Messari’s report showcases key areas of TRON’s growth and strategic advancements: Revenue and Market Expansion: With a 15% increase in market cap and record Q1 revenue of $128.1 million, TRON has solidified its place among the top revenue-generating blockchain networks. DeFi and Stablecoin Sector Growth: TRON’s DeFi sector saw a 25% increase in TVL, while its stablecoin market cap, dominated by USDT, grew by 8%, further anchoring its pivotal role in the global stablecoin market. Layer-2 Development for Bitcoin: The TRON DAO’s introduction of a Layer-2 solution for Bitcoin marks a pivotal development, aiming to integrate the TRON network, BitTorrent Chain, and Bitcoin networks to boost scalability and functionality. Further Insights Both reports highlight TRON’s resilience and strategic adaptability. Messari notes the network’s deflationary token model as a key factor in its economic stability. Token Terminal’s analysis of TRON’s transactional efficiency and user engagement sheds light on its capacity for sustaining growth and increasing adoption. For a more granular look at TRON’s performance metrics and strategic initiatives, the full reports can be accessed through Token Terminal and Messari’s platforms. Keep up with TRON DAO for the latest updates and developments as we continue to push the boundaries of decentralization and blockchain innovation worldwide. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the ecosystem integration of BitTorrent, a pioneer in decentralized Web3 services boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of May 2024, it has over 230.22 million total user accounts on the blockchain, more than 7.64 billion total transactions, and over $22.12 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Most recently in October 2022, TRON was designated as the national blockchain for the Commonwealth of Dominica, which marks the first time a major public blockchain partnered with a sovereign nation to develop its national blockchain infrastructure. On top of the government’s endorsement to issue Dominica Coin (“DMC”), a blockchain-based fan token to help promote Dominica’s global fanfare, seven existing TRON-based tokens - TRX, BTT, NFT, JST, USDD, USDT, TUSD, have been granted statutory status as authorized digital currency and medium of exchange in the country. TRONNetwork | TRONDAO | Twitter | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Hayward Wong press@tron.network Contact Details Hayward Wong press@tron.network Company Website https://trondao.org/

May 17, 2024 08:00 AM Eastern Daylight Time

Image

Neural Therapeutics CEO Ian Campbell discusses potential CSE listing and future plans

Neural Therapeutics Inc.

Neural Therapeutics CEO Ian Campbell discusses the company's conditional approval to list on the Canadian Securities Exchange (CSC) in an interview with Proactive's Stephen Gunnion. Campbell explained that the CSE listing is a strategic move, enabling broader market participation and capitalisation on its advancements. The company aims to raise $500,000, primarily for research and development efforts and securing intellectual property, including two patents. Campbell highlighted the growing interest in psychedelic treatments, noting the significant investment in this sector and the 44% rise of the Psychedelic Invest Index this year. He emphasised the mental health crisis and the inadequacy of outdated therapies, positioning psychedelics as a promising and disruptive alternative. Neural Therapeutics specialises in mescaline extracted from the San Pedro cactus, a substance with a long history of safe use. Campbell noted mescaline's unique properties, such as its longer duration in the body, which supports neuroplasticity and potential treatment for mental illnesses like addiction without causing hallucinations. The CSE listing is expected to enhance the company's visibility, attract investment, and accelerate drug development. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2024 08:00 AM Eastern Daylight Time

Video

Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline

Arecor Therapeutics PLC

Arecor Therapeutics PLC (AIM:AREC)C CEO Sarah Howell discusses the company's 2023 performance and future plans with Proactive's Stephen Gunnion. Howell highlighted that Arecor has seen significant growth, particularly with the launch of products incorporating its Arestat technology under a global licensing agreement, generating royalties. Six new technology partnerships were established with major pharma and biotech companies, offering potential for future licensing and market development. Arecor focuses on diabetes and obesity, with clinical results for their proprietary product, AT278, expected soon. This highly concentrated, rapid-acting insulin aims to provide better glucose control for type 2 diabetics with high BMI and support the next generation of insulin pump devices. Tetris Pharma, a subsidiary, has shown strong growth under new leadership, with product sales tripling to £2.9 million in 2023. Its lead product, glucagon, has contributed significantly to this growth. Howell also noted the importance of technology partnerships and licensing programs. Arecor has entered into three active license programs and is progressing well with its partners. One notable partnership is with Medtronic to develop a concentrated, stable insulin for intra-peritoneal delivery, aiming to reduce hospital visits for patients with brittle diabetes. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 17, 2024 03:20 AM Eastern Daylight Time

Video

1 2 3 4 5 6 ... 3510

Back